Ziprasidone and quetiapine. One goes better fast, one slow. Also the mystery of ghost pills, and a research update on pramipexole.

The FDA just approved the cyclobenzaprine (Tonmya, Flexeril) for fibromyalgia. We look at three risks that medication raises in psychiatry.

We’re often told antipsychotics are a last resort for agitation in dementia. And that’s true—they are. But when you do reach that last resort, you need to know how to use it—and how to talk about it with families.

We ask about alcohol.

We ask about weed.

Sometimes we even ask about TikTok.

But porn?

What happens when the patient doesn’t want therapy?

How do you approach patients who ask about cannabis for anxiety?

The FDA just approved Ketarx for surgical pain, but the company has its eyes on depression.

A reminder that focus problems don’t always mean ADHD. That suffering doesn’t always need a label. And that quick relief can sometimes do lasting harm.

Yesterday I wrote about what it feels like to live with social anxiety.

Today I want to talk about how we ask about it.

We talk about social anxiety like it’s just shyness with a clinical name. But for some patients, it’s life-halting.